Safety and Efficacy of Subcutaneous-Only Granulocyte-Macrophage Colony-Stimulating Factor for Collateral Growth Promotion in Patients With Coronary Artery Disease

Zbinden, Stephan; Zbinden, Rainer; Meier, Pascal; Windecker, Stephan; Seiler, Christian

doi:10.1016/j.jacc.2005.01.068

Cited by 125 publications

(92 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the risk of AMI was higher in coronary artery disease patients whose WBC counts increased after the administration of granulocyte colony-stimulating factor or granulocytemacrophage colony-stimulating factor administered to promote neo-revascularization. 12,13 Neutrophilic infiltration of culprit lesions in patients who died after AMI suggests that platelets and neutrophils interact at the site of ruptured plaques.…”

Section: Discussionmentioning

confidence: 99%

ST-Elevation Myocardial Infarction and Myelodysplastic Syndrome with Acute Myeloid Leukemia Transformation

Jao¹,

Knovich²,

Savage³

et al. 2014

Texas Heart Institute Journal

View full text Add to dashboard Cite

Acute myocardial infarction and acute myeloid leukemia are rarely reported as concomitant conditions. The management of ST-elevation myocardial infarction (STEMI) R eports of concomitant acute myocardial infarction (AMI) and acute myeloid leukemia (AML) are sparse. The management of ST-elevation myocardial infarction (STEMI) in patients with AML is challenging, because of the increased risk of bleeding from the thrombocytopenia, platelet dysfunction, and systemic coagulopathy in AML. No guidelines exist for the appropriate management of this combined disease phenomenon. We report a case of STEMI in a patient with coronary artery disease, myelodysplastic syndrome, and newly recognized AML transformation. In addition, we review the relevant medical literature and discuss the appropriateness of applying evidence-based acute coronary syndrome (ACS) management principles to patients with simultaneous STEMI and AML. Case ReportA 76-year-old man with known coronary artery disease and myelodysplastic syndrome emergently presented with a 3-week history of intermittent exertional angina.He had undergone 3-vessel coronary artery bypass grafting 10 years earlier. Cardiac catheterization performed a year before the current presentation yielded severe native-vessel disease: 90% stenosis of the distal left main coronary artery (LMCA), 50% ostial stenosis of the proximal left anterior descending coronary artery (LAD) with Rentrop grade 2 collateral vessels, ostial bifurcation lesions in the left circumflex coronary artery, and a chronically occluded right coronary artery (RCA). The graft from the left internal mammary artery to the mid-LAD and the sequential graft from the free radial artery to the distal diagonal artery were patent; however, the saphenous vein-to-RCA graft was occluded. The patient's estimated left ventricular ejection Case Reports

show abstract

Section: Discussionmentioning

confidence: 99%

ST-Elevation Myocardial Infarction and Myelodysplastic Syndrome with Acute Myeloid Leukemia Transformation

Jao¹,

Knovich²,

Savage³

et al. 2014

Texas Heart Institute Journal

View full text Add to dashboard Cite

show abstract

“…[7][8][9][10][11] Animal data have similarly yielded discordant results, depending on the dose and timing of G-CSF. 12 To clarify the role of G-CSF in promoting left ventricular recovery after acute myocardial infarction, we performed an adequately powered randomized clinical trial in patients with moderate left ventricular dysfunction following anteriorwall STEMI.…”

Section: Methodsmentioning

confidence: 99%

“…Notably, 3 other trials of G-CSF in patients with coronary artery disease were stopped early because of safety concerns: 1 trial for increased risk of in-stent restenosis 8 and 2 trials for increased risk of acute coronary syndromes. 10,11 This situation is particularly noteworthy given that research on G-CSF for patients with coronary disease or chronic left ventricular dysfunction (or both) is continuing.…”

Section: E430mentioning

confidence: 99%

Granulocyte colony-stimulating factor therapy for stem cell mobilization following anterior wall myocardial infarction: the CAPITAL STEM MI randomized trial

Hibbert

Hayley

Beanlands

et al. 2014

CMAJ

View full text Add to dashboard Cite

“…This method may offer promise as a means of improving the efficacy of EPC transplantation for therapeutic neovascularization in the diabetic setting. However, previous data, while suggesting that G-CSF o r granulocyte-macrophage colony -stimulating factor (GM-CSF) administration did increase EPC mobilization, the therapeutic effect in patients with coronary artery disease was conflicting (174,175). More recent data have shown that transplantation of G-CSF-mobilized EPCs for the treatment of critical limb ischaemia in patients with DM is safe and effective (23).…”

Section: Epc Transplantation In Diabetesmentioning

confidence: 99%

Endothelial Progenitor Cells in Diabetic Vasculopathy

Meiliana

Wijaya

2009

Indones Biomed J

View full text Add to dashboard Cite

BACKGROUND: The discovery of endothelial progenitor cell (EPC) a decade ago by Asahara, et al has refuted the previous belief that vasculogenesis only occurs during embryogenesis. The reduced circulating concentration of EPCs is a surrogate marker of endothelial function and has been implicated in the pathogenesis of many vascular diseases.CONTENT: Diabetes is linked to impaired vascular function, including alterations in both endothelial cells and EPCs. A number of studies have shown that individuals with diabetes have decreased level of circulating EPCs and that the severity of disease is inversely proportional to EPC levels. In vitro, hyperglycemia increases the rate of EPC senescence and the angiogenic function of EPCs from patients with either type 1 or type 2 diabetes is impaired such that they are poorly proliferative and fail to incorporate into forming vessel-like structures. Given the comprehensive role of EPC alterations in diabetes complications, modulation of the levels and/or function of EPCs may be considered a potential therapeutic strategy.SUMMARY: The available data demonstrating that decrease or dysfunction of EPCs may have a prominent role in the pathogenesis of all diabetes complications. Further approaches, such as EPC administration, may represent novel treatments for diabetic vasculopathy in the future. To date, many barriers remain to such a therapeutic approach. Firstly, there is no specific marker for EPC at present. Secondly, techniques of EPC isolation are not standardized, preventing direct comparison between various studies. The long-term effects of transplanted EPCs are currently unknown.

show abstract

Safety and Efficacy of Subcutaneous-Only Granulocyte-Macrophage Colony-Stimulating Factor for Collateral Growth Promotion in Patients With Coronary Artery Disease

Abstract: A subcutaneous-only, short-term protocol of GM-CSF is effective in promoting coronary collateral artery growth among patients with CAD. However, the drug's safety regarding the occurrence of acute coronary syndrome is questionable.

Cited by 125 publications

References 11 publications

ST-Elevation Myocardial Infarction and Myelodysplastic Syndrome with Acute Myeloid Leukemia Transformation

ST-Elevation Myocardial Infarction and Myelodysplastic Syndrome with Acute Myeloid Leukemia Transformation

Granulocyte colony-stimulating factor therapy for stem cell mobilization following anterior wall myocardial infarction: the CAPITAL STEM MI randomized trial

Endothelial Progenitor Cells in Diabetic Vasculopathy

Contact Info

Product

Resources

About